Table 2.
Univariate comparison of patient and tumor characteristics of cT2N0 upfront esophagectomy patients that were pathologically upstaged that did or did not receive adjuvant chemotherapy.
| Variable | Upstaged Upfront Esophagectomy, No Adjuvant (n=182) | Upstaged Upfront Esophagectomy, Received Adjuvant (n=144) | P value |
|---|---|---|---|
|
| |||
| Age (years) | 67.3 ± 11.2 | 62.6 ± 10.6 | <0.001 |
|
| |||
| Gender (male) | 150 (82.4%) | 127 (88.2%) | 0.15 |
|
| |||
| Race (Caucasian) | 160 (89.4%) | 138 (96.5%) | 0.02 |
|
| |||
| Population | |||
| <250,000 | 54 (31.4%) | 41 (30.8%) | 0.92 |
| ≥250,000 | 118 (68.6%) | 92 (69.2%) | |
|
| |||
| Greatest circle distance (miles) | 54.1 ± 81.6 | 42.6 ± 140.0 | 0.37 |
|
| |||
| Income | |||
| <$38,000 | 27 (15.3%) | 18 (13.0%) | 0.56 |
| ≥$38,000 | 149 (84.7%) | 120 (87.0%) | |
|
| |||
| Insurance | |||
| Uninsured | 5 (2.8%) | 3 (2.1%) | 0.001 |
| Private | 52 (29.1%) | 71 (49.7%) | |
| Government* | 122 (68.2%) | 69 (48.3%) | |
|
| |||
| Education | |||
| ≥21% no HS degree | 26 (14.8%) | 17 (12.2%) | 0.52 |
| <21% no HS degree | 150 (85.2%) | 122 (87.8%) | |
|
| |||
| Charlson/Deyo Score | |||
| 0 | 119 (65.4%) | 94 (65.3%) | 0.99 |
| 1 | 47 (25.8%) | 37 (25.7%) | |
| ≥2 | 16 (8.8%) | 13 (9.0%) | |
|
| |||
| Facility Type | |||
| Nonacademic | 75 (41.2%) | 58 (40.3%) | 0.87 |
| Academic | 107 (58.8%) | 86 (59.7%) | |
|
| |||
| Year of Diagnosis | |||
| 2006 | 23 (12.6%) | 15 (10.4%) | 0.40 |
| 2007 | 18 (9.9%) | 22 (15.3%) | |
| 2008 | 39 (21.4%) | 33 (22.9%) | |
| 2009 | 26 (14.3%) | 27 (18.8%) | |
| 2010 | 28 (15.4%) | 19 (13.2%) | |
| 2011 | 28 (15.4%) | 13 (9.0%) | |
| 2012 | 20 (11.0%) | 15 (10.4%) | |
|
| |||
| Histology | |||
| Squamous | 46 (29.3%) | 15 (12.4%) | 0.001 |
| Adenocarcinoma | 111 (70.7%) | 106 (87.6%) | |
|
| |||
| Tumor Grade | |||
| Well-differentiated | 4 (2.4%) | 3 (2.1%) | 0.18 |
| Moderately differentiated | 72 (42.6%) | 45 (31.9%) | |
| Poorly differentiated | 87 (51.5%) | 90 (63.8%) | |
| Undifferentiated | 6 (3.6%) | 3 (2.1%) | |
|
| |||
| Pathologic T Stage | |||
| 1 | 14 (7.7%) | 10 (6.9%) | 0.95 |
| 2 | 43 (23.6%) | 31 (21.5%) | |
| 3 | 122 (67.0%) | 101 (70.1%) | |
| 4 | 3 (1.6%) | 2 (1.4%) | |
|
| |||
| Pathologic N Stage | |||
| N0 | 66 (36.3%) | 21 (14.6%) | <0.001 |
| N1 | 102 (56.0%) | 101 (70.1%) | |
| N2 | 6 (3.3%) | 16 (11.1%) | |
| N3 | 8 (4.4%) | 6 (4.2%) | |
|
| |||
| Tumor size (mm) | 46.0 ± 74.9 | 37.8 ± 20.6 | 0.21 |
|
| |||
| Positive Surgical Margins | 22 (12.3%) | 35 (24.5%) | 0.004 |
|
| |||
| Number of Nodes Examined | 17.9 ± 12.4 | 18.2 ± 11.1 | 0.84 |
|
| |||
| Number of Nodes Positive | 2.1 ± 4.0 | 3.5 ± 5.3 | 0.007 |
|
| |||
| Length of Stay (days) | 18.6 ± 17.1 | 11.3 ± 8.3 | <0.001 |
|
| |||
| 30-day readmission | 20 (11.3%) | 10 (7.2%) | 0.22 |
*
Government insurance includes Medicare, Medicaid, or other government insurance plans.